South Africa

Virus up close

‘Gamechanger’ HIV prevention drug to be made available cheaply in 120 countries

By /

Gilead Sciences says it has signed agreements with six manufacturers to make and sell generic lenacapavir in 120 “high-incidence, resource-limited” countries. Lenacapavir, given as a twice-yearly injection, has shown strong results for HIV prevention. It stopped infection in a trial involving girls and women in South Africa and Uganda, and offered almost complete protection in a second trial that mainly involved men across Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the U.S.

South African flag

South Africa passes its first sweeping climate change law

By /

South African President Cyril Ramaphosa has signed into law a broad climate change act that will set caps for large emitters and require every town and city to publish an adaptation plan. The Climate Change Bill aims to enable South Africa to meet its emissions reduction commitments under the Paris climate agreement. South Africa, which is the world’s most carbon-intensive major economy and among the top 15 greenhouse gas emitters, is on track to miss those targets because of to its heavy reliance on coal for electricity.

Good news for public health

New twice-yearly shot to prevent HIV achieves 100% success rate in late-stage trial

By /

In this double-blind, randomized study of 5,300 cisgender women in South Africa and Uganda, 2,134 got the injection and the others took one of two types of daily PrEP pills. The trial from California-based company Gilead Sciences began on August 2021 and, so far, not a single woman who received the injections has contracted HIV. The participants who received either of the oral PrEP options, Truvada and Descovy, had infection rates of about 2% — consistent with the infection rates of oral PrEP in other clinical trials.

Scroll to Top